Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Clonal Kinetics and Single Cell Transcriptional Profiling of Adoptively Transferred CD19 CAR-T Cells

Alyssa Sheih, PhD, Laila-Aicha Hanafi, PhD, Valentin Voillet, PhD, Hannah A. DeBerg, PhD, Reed M. Hawkins, BS, Masanao Yajima, PhD, Vivian Gersuk, PhD, Peter S. Linsley, PhD, Raphael Gottardo, PhD, Cameron J. Turtle, MBBS, PhD

Blood (2018) 132 (Supplement 1): 702.

https://doi.org/10.1182/blood-2018-99-111350

Published: 2018

Journal Articles

Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after CD19 CAR-T Cell Immunotherapy

Cameron J. Turtle, MBBS, PhD, Kevin A. Hay, MD FRCPC, MSc, Laila-Aicha Hanafi, PhD, Juliane Gust, MDPhD, W. Conrad Liles, MDPhD, José A. López, MD, Junmei Chen, PhD, Dominic W. Chung, PhD, Mark M Wurfel, MDPhD, Susanna Harju-Baker, PhD, Hasan Ozpolat, MD, Daniel Li, PhD, David Myerson, MDPhD, Luis F. Gonzalez-Cuyar, MD, Cecilia Yeung, MD, Kathleen R. Fink, MD, Stanley R. Riddell, MD, David G. Maloney, MD PhD

Blood (2017) 130 (Supplement 1): 805.

https://doi.org/10.1182/blood.V130.Suppl_1.805.805

Published: 2017

Journal Articles

Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor–modified T-cell therapy

Kevin A. Hay, Laïla-Aïcha Hanafi, Daniel Li, Juliane Gust, W. Conrad Liles, Mark M. Wurfel, José A. López, Junmei Chen, Dominic Chung, Susanna Harju-Baker, Sindhu Cherian, Xueyan Chen, Stanley R. Riddell, David G. Maloney, Cameron J. Turtle

Blood (2017) 130 (21): 2295–2306.

https://doi.org/10.1182/blood-2017-06-793141

Published: 2017

Includes: Supplemental data

Journal Articles

CD19 CAR-T Cells Are Highly Effective in Ibrutinib-Refractory Chronic Lymphocytic Leukemia

Cameron J Turtle, MBBS, PhD, Laila-Aicha Hanafi, PhD, Daniel Li, PhD, Colette Chaney, RN, Shelly Heimfeld, PhD, Stanley R Riddell, MD, David G Maloney, MD PhD

Blood (2016) 128 (22): 56.

https://doi.org/10.1182/blood.V128.22.56.56

Published: 2016

Journal Articles

Biomarkers of Cytokine Release Syndrome and Neurotoxicity after CD19 CAR-T Cells and Mitigation of Toxicity By Cell Dose

Cameron J Turtle, MBBS, PhD, Kevin A Hay, MDFRCPC, MSc, Gust Juliane, MD PhD, Laila-Aicha Hanafi, PhD, Daniel Li, PhD, Colette Chaney, RN, Shelly Heimfeld, PhD, Stanley R Riddell, MD, David G. Maloney, MD PhD

Blood (2016) 128 (22): 1852.

https://doi.org/10.1182/blood.V128.22.1852.1852

Published: 2016

Journal Articles

Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL -rearranged B-ALL from CD19 CAR-T-cell therapy

Rebecca Gardner, David Wu, Sindhu Cherian, Min Fang, Laïla-Aïcha Hanafi, Olivia Finney, Hannah Smithers, Michael C. Jensen, Stanley R. Riddell, David G. Maloney, Cameron J. Turtle

Blood (2016) 127 (20): 2406–2410.

https://doi.org/10.1182/blood-2015-08-665547

Published: 2016

Journal Articles

Addition of Fludarabine to Cyclophosphamide Lymphodepletion Improves In Vivo Expansion of CD19 Chimeric Antigen Receptor-Modified T Cells and Clinical Outcome in Adults with B Cell Acute Lymphoblastic Leukemia

Cameron J Turtle, MBBS, PhD, Laila-Aicha Hanafi, PhD, Carolina Berger, MD, Daniel Sommermeyer, PhD, Barbara Pender, MS, Emily M Robinson, BS, Katherine Melville, Tanya M Budiarto, BSc, Natalia N Steevens, Colette Chaney, RN, Sindhu Cherian, MD, Brent L Wood, MD PhD, Lorinda Soma, MD, Xueyan Chen, MD PhD, Shelly Heimfeld, PhD, Michael C Jensen, MD, Stanley R. Riddell, MD, David G Maloney, MD PhD

Blood (2015) 126 (23): 3773.

https://doi.org/10.1182/blood.V126.23.3773.3773

Published: 2015

Journal Articles

Anti-CD19 Chimeric Antigen Receptor-Modified T Cell Therapy for B Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Fludarabine and Cyclophosphamide Lymphodepletion Improves In Vivo Expansion and Persistence of CAR-T Cells and Clinical Outcomes

Cameron J Turtle, MBBS, PhD, Carolina Berger, MD, Daniel Sommermeyer, PhD, Laila-Aicha Hanafi, PhD, Barbara Pender, MS, Emily M Robinson, BS, Katherine Melville, Tanya M Budiarto, BSc, Natalia N Steevens, Colette Chaney, RN, Sindhu Cherian, MD, Brent L Wood, MD PhD, Lorinda Soma, MD, Xueyan Chen, MD PhD, Shelly Heimfeld, PhD, Michael C Jensen, MD, Stanley R. Riddell, MD, David G Maloney, MD PhD

Blood (2015) 126 (23): 184.

https://doi.org/10.1182/blood.V126.23.184.184

Published: 2015

NARROW

Clonal Kinetics and Single Cell Transcriptional Profiling of Adoptively Transferred CD19 CAR-T Cells

Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after CD19 CAR-T Cell Immunotherapy

Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor–modified T-cell therapy

CD19 CAR-T Cells Are Highly Effective in Ibrutinib-Refractory Chronic Lymphocytic Leukemia

Biomarkers of Cytokine Release Syndrome and Neurotoxicity after CD19 CAR-T Cells and Mitigation of Toxicity By Cell Dose

Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL -rearranged B-ALL from CD19 CAR-T-cell therapy

Addition of Fludarabine to Cyclophosphamide Lymphodepletion Improves In Vivo Expansion of CD19 Chimeric Antigen Receptor-Modified T Cells and Clinical Outcome in Adults with B Cell Acute Lymphoblastic Leukemia

Anti-CD19 Chimeric Antigen Receptor-Modified T Cell Therapy for B Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Fludarabine and Cyclophosphamide Lymphodepletion Improves In Vivo Expansion and Persistence of CAR-T Cells and Clinical Outcomes

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only